The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
US OPEN: Dell soars and keeps pushing tech stocks higher 🚀
EU50 near record highs: broad-based gains and buybacks support european equities 🔎
Dell surges 40% amid very strong earnings report ⚡The next AI winner?
Daily Summary: Is the End of the War Drawing Near? (28.05.2026)